Compare MSEX & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | ETON |
|---|---|---|
| Founded | 1897 | 2017 |
| Country | United States | United States |
| Employees | 395 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 872.7M |
| IPO Year | N/A | 2018 |
| Metric | MSEX | ETON |
|---|---|---|
| Price | $57.66 | $37.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $61.33 | $39.33 |
| AVG Volume (30 Days) | 157.6K | ★ 399.8K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $10.60 | $40.90 |
| Revenue Next Year | $10.94 | $47.23 |
| P/E Ratio | ★ $22.68 | $750.00 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $44.94 | $13.76 |
| 52 Week High | $62.18 | $37.98 |
| Indicator | MSEX | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 73.53 | 73.80 |
| Support Level | $49.91 | $15.77 |
| Resistance Level | $62.18 | N/A |
| Average True Range (ATR) | 1.20 | 1.52 |
| MACD | 0.47 | 0.40 |
| Stochastic Oscillator | 93.28 | 93.30 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.